Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and flawless execution.
We are an uncommon health communications agency with a deep understanding of today’s complex healthcare environment.
Providing smart thinking, refreshing storytelling, and breakthrough solutions: from strategies through to entire campaigns.
We pioneer new routes and break new ground to deliver breakthroughs for our clients.
PharmaTimes Award Winners 2019: International Challenge
EMEA Sabre Award Winners 2019: Medical Technology
PRWeek Award Winners 2019: Issues and Reputation Management
Find out more at www.hanovercomms.com
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.
On Wednesday 16th September, Ursula Von Der Leyen, President of the European Union, announced in her State of Union address that they plan to develop BARDA, a Biomedical Advanced Research and Development Agency. This follows on from the Conservative Government pledging in their manifesto in late 2019 to develop ARPA, the Advanced Research Projects Agency. Both of these agencies are direct descendants of DARPA, the Defense Advanced Research Projects Agency founded in the USA in 1958 to create “Nation technology-based options for preventing – and creating - technological surprise.” Technological surprise is a wonderfully euphemistic phrase which refers to military “surprise” in the context of the Cold War. However, in the context of a global pandemic and the politicisation of the race to find a vaccine many are now drawing Cold War comparisons. But can DARPA, ARPA or BARDA actually deliver technological surprise? Jennifer Blainey, Director, Hanover Health explores.
In our new article, Lloyd Tingley explores the wider societal and behavioural factors that will impact the success of green prescribing and the obesity strategy, and the role companies will play in driving a society wide approach that impacts infrastructure, adherence, health inequalities, and more.
As discussed in a recent article, the next few years will define the future of life sciences and especially the regulation of breakthrough advanced therapy medicinal products (ATMPs) and orphan medicinal products (OMPs) in the EU. Here Senior Healthcare Director Emma Eatwell examines the impact of the recently-published European Commission Roadmap to develop an EU Pharmaceutical Strategy and considers what the the future looks like for ATMPs and OMPs.
COVID-19 has understandably dominated the news agenda like no other story in a generation. But what about other disease areas that are both important and deserve public attention? How do we break through this wall, particularly as coronavirus looks set to govern the news agenda for the next few months at least, if not longer?
Infamously coined America’s ‘public enemy number one’ by President Nixon, are controlled substances a fundamental missing part of modern medicine? By Emma Gorton, Senior Director at Hanover Communications
Alex Davies, Director at Hanover Health, considers the art of corporate storytelling and how we must challenge our clients to achieve a powerful narrative.
For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact.
New programme for communicators looking to breakthrough in their careers.
Address:
70 Gray's Inn Road
London
WC1X 8BT
United Kingdom